Literature DB >> 2016705

Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins.

T Noonan1, N Brown, L Dudycz, G Wright.   

Abstract

A series of N2-substituted guanosine 5'-triphosphates was synthesized from the corresponding nucleosides. The nucleosides were prepared by treatment of N2-substituted guanines with tetra-O-acetylribose under conditions which maximized the yield of the 9-beta-guanosine isomers. These nucleotides and several sugar- and base-modified analogues of GTP were tested for their ability to bind to cellular and oncogenic forms of the GTP/GDP binding proteins, Ha-ras-p21. Several N2-substituted GTPs showed affinities higher than that of GDP itself, and the N2-[p-(n-butyl)phenyl] derivative bound to the oncogenic mutant, Leu-61 p21, twice as strongly as to the cellular protein. Changes in relative affinities of the nucleotides are discussed with reference to reported crystallographic structures of p21.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016705     DOI: 10.1021/jm00108a010

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.

Authors:  Russell Spencer-Smith; Lie Li; Sheela Prasad; Akiko Koide; Shohei Koide; John P O'Bryan
Journal:  Small GTPases       Date:  2017-12-31

Review 2.  KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Authors:  Misako Nagasaka; Yiwei Li; Ammar Sukari; Sai-Hong Ignatius Ou; Mohammed Najeeb Al-Hallak; Asfar S Azmi
Journal:  Cancer Treat Rev       Date:  2020-01-23       Impact factor: 12.111

Review 3.  Small-molecule modulation of Ras signaling.

Authors:  Jochen Spiegel; Philipp M Cromm; Gunther Zimmermann; Tom N Grossmann; Herbert Waldmann
Journal:  Nat Chem Biol       Date:  2014-06-15       Impact factor: 15.040

Review 4.  Direct inhibition of RAS: Quest for the Holy Grail?

Authors:  Russell Spencer-Smith; John P O'Bryan
Journal:  Semin Cancer Biol       Date:  2017-12-14       Impact factor: 15.707

5.  Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population.

Authors:  Sara Tomei; Sharon Adams; Lorenzo Uccellini; Davide Bedognetti; Valeria De Giorgi; Narnygerel Erdenebileg; Maria Libera Ascierto; Jennifer Reinboth; Qiuzhen Liu; Generoso Bevilacqua; Ena Wang; Chiara Mazzanti; Francesco M Marincola
Journal:  Med Oncol       Date:  2012-05-22       Impact factor: 3.064

Review 6.  Conquering oncogenic KRAS and its bypass mechanisms.

Authors:  Pingping Hou; Y Alan Wang
Journal:  Theranostics       Date:  2022-07-18       Impact factor: 11.600

7.  A Pan-GTPase Inhibitor as a Molecular Probe.

Authors:  Lin Hong; Yuna Guo; Soumik BasuRay; Jacob O Agola; Elsa Romero; Denise S Simpson; Chad E Schroeder; Peter Simons; Anna Waller; Matthew Garcia; Mark Carter; Oleg Ursu; Kristine Gouveia; Jennifer E Golden; Jeffrey Aubé; Angela Wandinger-Ness; Larry A Sklar
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

Review 8.  A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished.

Authors:  Wenjuan Ning; Zhang Yang; Gregor J Kocher; Patrick Dorn; Ren-Wang Peng
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.